Kapvay designed to treat ADHD
FLORHAM PARK, N.J. — Drug maker Shionogi has launched a new medication for attention deficit hyperactivity disorder, the company said Monday.
Shionogi announced the launch of Kapvay (clonidine hydrochloride), an extended-release drug for treating ADHD in children and adolescents. The company said the drug was the only ADHD treatment approved as an add-on to stimulant medications, though it can be used alone as well.
“Shionogi is extremely proud to bring Kapvay to market in the United States,” Shionogi chief medical officer Donald Manning said. “The extended-release version of clonidine hydrochloride found in Kapvay offers an exciting new treatment option for children and adolescents with ADHD who are not experiencing adequate symptom relief from stimulants alone.”